Regeneron (REGN) Tops Q1 EPS by 20c; Boosts U.S. EYLEA Sales Outlook
Regeneron (NASDAQ: REGN) reported Q1 EPS of $2.88, $0.20 better than the analyst estimate of $2.68. Revenue for the quarter came in at $870 million versus the consensus estimate of $820.3 million.
Net product sales were $545 million in the first quarter of 2015, compared to $362 million in the first quarter of 2014. EYLEA net product sales in the United States were $541 million in the first quarter of 2015, compared to $359 million in the first quarter of 2014.
2015 Financial Guidance
The Company's updated full year 2015 financial guidance consists of the following components:
EYLEA U.S. net product sales | 30% - 35% growth over 2014 (previously 25% - 30% growth over 2014) |
Non-GAAP unreimbursed R&D (2) | $525 million - $575 million (reaffirmed) |
Non-GAAP SG&A (2) | $650 million - $725 million (reaffirmed) |
Cash tax as a % of non-GAAP pre-tax income (2) | 10% - 20% (reaffirmed) |
Capital expenditures | $650 million - $750 million (previously $650 million - $800 million) |
For earnings history and earnings-related data on Regeneron (REGN) click here.